Talis Biomedical Corp Stock Alpha and Beta Analysis
| TLIS Stock | USD 2.84 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Talis Biomedical Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Talis Biomedical over a specified time horizon. Remember, high Talis Biomedical's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Talis Biomedical's market risk premium analysis include:
Beta 0.0343 | Alpha 1.3 | Risk 10.35 | Sharpe Ratio 0.14 | Expected Return 1.4 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Talis |
Talis Biomedical Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Talis Biomedical market risk premium is the additional return an investor will receive from holding Talis Biomedical long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Talis Biomedical. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Talis Biomedical's performance over market.| α | 1.30 | β | 0.03 |
Talis Biomedical expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Talis Biomedical's Buy-and-hold return. Our buy-and-hold chart shows how Talis Biomedical performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Talis Biomedical Market Price Analysis
Market price analysis indicators help investors to evaluate how Talis Biomedical pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Talis Biomedical shares will generate the highest return on investment. By understating and applying Talis Biomedical pink sheet market price indicators, traders can identify Talis Biomedical position entry and exit signals to maximize returns.
Talis Biomedical Return and Market Media
The median price of Talis Biomedical for the period between Wed, Oct 8, 2025 and Tue, Jan 6, 2026 is 1.6 with a coefficient of variation of 26.44. The daily time series for the period is distributed with a sample standard deviation of 0.48, arithmetic mean of 1.8, and mean deviation of 0.35. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
About Talis Biomedical Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Talis or other pink sheets. Alpha measures the amount that position in Talis Biomedical Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Talis Biomedical Upcoming Company Events
As portrayed in its financial statements, the presentation of Talis Biomedical's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Talis Biomedical's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Talis Biomedical's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Talis Biomedical. Please utilize our Beneish M Score to check the likelihood of Talis Biomedical's management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Talis Biomedical
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Talis Pink Sheet Analysis
When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.